CA-JSR-LIFE-SCIENCES
10.5.2022 14:02:15 CEST | Business Wire | Press release
JSR Life Sciences, LLC (JSR) today announced the launch of a new business division, Similis Bio (Similis), which will operate a partnering program designed to help biopharmaceutical companies improve the efficiency and cost of biosimilar development. Similis will rely on core expertise in developing and manufacturing biologics to mitigate the challenges inherent in biosimilar drug development.
Similis provides biosimilar drug developers with solutions designed to accelerate development timelines and lower costs. By offering complete analytical and process development packages, Similis supplies companies with data to determine an appropriate biosimilar target, accelerate early program development, and reduce analytical costs. Data packages include reference product data, analytical procedures, process expertise, and CMC templates from a centralized model designed to give partners access to higher quality biosimilar packages at a lower cost than other development models.
Additionally, Similis will establish co-development agreements with partner companies to start the development of multiple biosimilar programs in parallel, giving partners an exclusive right, but not an obligation, to purchase multiple programs. JSR designed this collaboration model to reduce the risk from program cancellations and extend market analysis timelines.
“This model will enable changes in strategy far beyond traditional drug development approaches by centralizing reference product data and expertise under one roof,” said JSR Life Sciences’ Chief Technology Officer Jean-Pierre Wery. “Similis brings the broad expertise of JSR Life Sciences companies together to jump-start the development of promising biosimilars. By improving timelines and development costs for drug makers, more biosimilars can be brought to market faster. Ultimately, that means more choice and lower costs for patients.”
Biosimilars—the generic form of FDA-approved biologics—are derived from living organisms, making them inherently complex. Unlike small-molecule generic drugs, biosimilars cannot fully replicate their brand-name counterparts, so an array of analytical data must be collected to ensure they sufficiently reflect biosimilarity to the FDA-approved reference products to which they are being compared. This process requires costly and significant investment in expertise, state-of-the-art technology, and extensive data gathering, including rigorous clinical trials to ensure a biosimilar's safety and efficacy. JSR launched Similis Bio to mitigate these barriers to market entry and promote more productive development programs.
For more information about Similis Bio visit: JSRLifeSciences.com/similis .
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Parse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune Biology29.10.2026 13:00:00 CET | Press release
Licensable perturbation dataset to include transcriptomes and proteomic secretomes for understanding the human immune response Parse Biosciences, the leading provider of scalable and accessible single-cell sequencing and a QIAGEN company, and Nomic Bio, a leader in high throughput proteomic profiling, today announced their partnership to generate Cascade, a 100 Million cell foundational dataset to understand the human immune response. The dataset's scale and depth will give pharma partners cellular- and protein-level insight into immune biology, accelerating their ability to identify and validate new drug targets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029559438/en/ Cascade has already drawn foundational partner commitments from leading pharmaceutical and biotechnology companies, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, underscoring the demand for large-scale, multimodal immune data in drug
CSC Named Winner of the Top InfoSec Innovator Award for Most Innovative DNS Security29.10.2026 13:00:00 CET | Press release
CSC’s Subdomain Monitoring recognized for innovation in mitigating subdomain hijacking risks from dangling DNS CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and Domain Name System (DNS) threats, today announced that its Subdomain Monitoring solution took top honors for Most Innovative DNS Security in Cyber Defense Magazine’s 2026 Top InfoSec Innovator Awards. CSC introduced Subdomain Monitoring after analyzing close to half a million DNS records and finding that many companies were exposed to subdomain takeovers due to dangling DNS. CSC’s solution helps enterprises reduce this risk and secure their online ecosystems. It was the first and only technology on the market to ease the burden of tracking and maintaining DNS records and purging unused zone records to prevent subdomain hijacking. Subdomain Monitoring, powered by CSC’s one-of-a-kind DomainSecSM threat intelligence platform, alerts DNS administrators and security engineers when it
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 12:27:00 CET | Press release
EMA has validated two marketing authorization applications from Daiichi Sankyo in the EU for single-pill triple-combinations of established lipid-lowering agents: bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin If approved, the proposed therapies could be the first oral single-pill triple-combinations for lipid-lowering in the EU, aiming to simplify treatment for patients requiring multiple lipid-lowering agents The submissions reflect the commitment of Daiichi Sankyo to addressing unmet needs in cardiovascular disease The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinu
NIQ and Google Partner to Advance Agentic Commerce29.10.2026 11:45:00 CET | Press release
Built with Google Cloud and Gemini for business, NIQ and Google commit to transforming AI-driven product discovery, availability, and measurement Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable,
TradeStation Europe Expands Options Capability, Including Extended-Hours Trading29.10.2026 11:43:00 CET | Press release
Expanded intraday and options trading capability, combined with lower options and equities commissions across the Netherlands and the EEA TradeStation Europe B.V. (“TradeStation Europe”), the recently licensed European brokerage subsidiary of TradeStation Group, Inc. (“TradeStation”), today announced a round of product updates, including extended-hours options trading, along with reduced options and equities pricing, new single-stock option spreads and expanded intraday trading to enhance the offering for retail and institutional traders across the Netherlands and the European Economic Area (EEA). Extended-hours options trading is now live. Clients can trade eligible equity options during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and an extended curb session from 4:00 p.m. to 4:15 p.m. ET. The launch follows Cboe Global Markets, Inc.’s (Cboe: CBOE) introduction of extended trading hours for options on 24 individual stocks and five ETFs, expanding access to some of the most ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom